Fig. 1 · Structure
Documents & Downloads
Pirmitegravir
ALLINI Inhibitor
Pirmitegravir is a potent allosteric integrase inhibitor (ALLINI) that targets the LEDGF/p75 binding site. It exhibits a picomolar IC50 in human peripheral blood mononuclear cells (PBMCs) and boasts a therapeutic index exceeding 24,000 against HIV-1. Pirmitegravir demonstrates exceptional antiviral efficacy and safety, making it a valuable tool for HIV research and therapeutic development.
In Stock
Free Aliquoting for Your Order
Tell us your preferred amount per vial. We’ll confirm the options.
Specifications
| Manufacturer | Adooq Bioscience |
|---|---|
| Actions | Inhibitor |
| CAS Number | 2245231-10-9 |
| Applications | ALLINI Inhibitor |
| Formula | C27H31ClN4O3 |
| Molecular Weight | 495.01 |
| Synonyms | STP0404 |
| SMILES | O=C([C@H](C1=C(N=C(C2=C1C3=CC=C(C=C3)Cl)N(C(C)=C2C)CC4=CN(N=C4)C)C)OC(C)(C)C)O |
Storage & Solubility
In Vitro Solubility
Reported Solubility
No reported solubility data are available for this product.
Preparing Stock Solutions
| Concentration | |
|---|---|
Values use four significant digits. Prepare to the final solution volume; this is not the volume of solvent to add.
Stock preparation is unavailable for this product molecular weight.
Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.
Storage
Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.